Ambrosia Biosciences

About Ambrosia Biosciences

Ambrosia Biosciences is a drug discovery company focused on developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. Their mission is to deliver enduring health through safe, effective, and affordable small molecule drugs, leveraging advanced structural biology and AI-powered molecular design.

Products & Services

GLP1R Agonist:In DC/IND-enabling studies, developing a differentiated GLP-1 molecule with best-in-class potential through a novel structural approach, lower effective human dosing, superior 24-hour target coverage, and improved combinability.

GIPR Antagonist:In discovery phase, aimed at combination dosing with GLP1-RA to amplify efficacy while maintaining tolerability, with potential for maintenance dosing.

Amylin Agonist:In discovery phase, intended as a once-daily monotherapy or in combination with synergistic therapies like GLP-1RA.

Specialties

Drug Discovery Small Molecule Therapies Metabolic Disorders Obesity Treatments GPCR Drug Discovery Structural Biology AI-Powered Molecular Design

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2026-03-31 FD: 2026-03-31	8 investors

Series B Latest

2026-03-31

$100.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nick Traggis

Founder and Chief Executive Officer

LinkedIn (Pro only)

P

Patrice Lee

President, Research & Development, Head of Pharmacology

LinkedIn (Pro only)

E

Erik Hicken

Head of Chemistry

LinkedIn (Pro only)

A

Andrea Flynn

Chief Business Officer

F

Faraz Naqvi

Founder and Medical Director

B

Ben Carver

General Counsel

View 16 more team members with Pro

Unlock Full Team Directory

Recent News